Kondratyeva Elena, Bukharova Tatyana, Efremova Anna, Melyanovskaya Yuliya, Bulatenko Natalia, Davydenko Ksenia, Filatova Alexandra, Skoblov Mikhail, Krasovsky Stanislav, Petrova Nika, Polyakov Alexander, Adyan Tagui, Amelina Elena, Shadrina Vera, Zhekaite Elena, Zodbinova Aysa, Chernyak Alexander, Zinchenko Rena, Kutsev Sergei, Goldshtein Dmitry
Research Centre for Medical Genetics, 115522 Moscow, Russia.
Faculty of Pediatrics, Perm State Medical University, 614990 Perm, Russia.
Genes (Basel). 2021 May 28;12(6):837. doi: 10.3390/genes12060837.
Cystic fibrosis (CF) is the most common monogenic autosomal recessive disease, associated with pathogenic variants in the CFTR gene. The splicing variant c.3140-16T>A (3272-16T>A) has been described previously and, according to the Russian CF Patients Registry, occurs with a frequency of 0.34%. The phenotypic features of CF patients with the c.3140-16T>A variant were compared with those of patients with the genotype F508del/F508del. Patients with the allele c.3140-16T>A had higher average age and age at diagnosis, and the allele was present in a greater proportion of adults. Patients carrying the c.3140-16T>A allele were characterised by better physical development indicators, both in adults and in children, had preserved pancreatic function, as well as the absence of a number of complications, and required pancreatic enzyme replacement therapy less often than patients with the F508del/F508del genotype. Sweat test values also were lower in patients with the c.3140-16T>A genotype. According to the results of clinical and laboratory studies, the phenotype of patients with the genetic variant c.3140-16T>A can be considered "mild". Functional CFTR protein activity in the presence of c.3140-16T>A was evaluated using intestinal current measurements (ICM) and the forskolin-induced swelling assay on organoids obtained from patients' rectal biopsies. c.3140-16T>A had high residual CFTR channel activity and was amenable to effective pharmacological correction with thea VX-770 potentiator. To evaluate the effect of the variant on CFTR pre-mRNA splicing we performed a minigene assay, as well as RT-PCR analysis of RNA isolated from the nasal epithelium and rectal biopsy of patients. We showed that the c.3140-16T>A variant creates a novel acceptor AG dinucleotide within CFTR intron 19, resulting in a 14-nucleotide extension of exon 20. This frameshift produces a premature termination codon and triggers mRNA degradation by the nonsense-mediated decay (NMD) mechanism. Moreover, we observed that the c.3140-16T>A allele could produce a residual amount of normally spliced transcript, thus explaining the patient's mild phenotype.
囊性纤维化(CF)是最常见的单基因常染色体隐性疾病,与CFTR基因的致病变异相关。剪接变体c.3140-16T>A(3272-16T>A)此前已有描述,根据俄罗斯CF患者登记处的数据,其出现频率为0.34%。将携带c.3140-16T>A变体的CF患者的表型特征与F508del/F508del基因型患者的表型特征进行了比较。携带等位基因c.3140-16T>A的患者平均年龄和诊断年龄较高,且该等位基因在成年人中所占比例更大。携带c.3140-16T>A等位基因的患者,无论成人还是儿童,其身体发育指标都更好,胰腺功能得以保留,且没有一些并发症,与F508del/F508del基因型患者相比,需要进行胰腺酶替代治疗的频率更低。c.3140-16T>A基因型患者的汗液测试值也较低。根据临床和实验室研究结果,基因变体c.3140-16T>A患者的表型可被视为“轻度”。利用肠道电流测量(ICM)和对患者直肠活检获得的类器官进行福斯高林诱导肿胀试验,评估了存在c.3140-16T>A时CFTR蛋白的功能活性。c.3140-16T>A具有较高的CFTR通道残余活性,并且可用VX-770增强剂进行有效的药理学校正。为了评估该变体对CFTR前体mRNA剪接的影响,我们进行了小基因检测以及对患者鼻上皮和直肠活检样本中分离的RNA进行逆转录聚合酶链反应(RT-PCR)分析。我们发现,c.3140-16T>A变体在CFTR基因第19内含子内产生了一个新的受体AG二核苷酸,导致外显子20延长了14个核苷酸。这种移码产生了一个提前终止密码子,并通过无义介导的衰变(NMD)机制触发mRNA降解。此外,我们观察到c.3140-16T>A等位基因可以产生一定量的正常剪接转录本,从而解释了患者的轻度表型。